Food and Drug Administration
Oncologic Drugs Advisory Committee
September 24, 2002
Slides
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
IRESSA® (ZD1839) Monotherapy for Non-Small Cell Lung Cancer (NSCLC), Introduction, Dr. George Blackledge, MD, AstraZeneca Pharmaceuticals htm ppt
The Need for 3rd-Line Therapy in Non-Small Cell Lung Cancer, Dr. Frances Shepherd, MD, U. of Toronto htm ppt
IRESSA® Clinical Efficacy, Dr. Ronadl Natale, MD, Cedar Sinai Comprehensive Cancer Ctr. htm ppt
IRESSA® (ZD1839) Safety Profile, Dr. Alan Sandler, MD, Vanderbilt University htm ppt
IRESSA® Summary, Dr. George Blackledge, MD, AstraZeneca Pharmaceuticals htm ppt
NDA 21-399 ZD1839 for Treatment of NSCLC, FDA Presentation htm ppt